Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive

ADVERTISEMENT

Deals
Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

Spend Trends 2007: Hang 10

May 1, 2007

Direct-to-consumer advertising officially becomes a "tweenager" this August—and, oh my, how it has grown. DTC was officially born in 1997 when FDA gave the green light to companies to advertise their drugs to consumers. In the first year, pharmaceutical marketers bounded onto the scene and spent more than $1 billion. Years passed. Debates ensued. Patients learned more about drugs. And, yes, spending grew. The latest available figures for 2006 show that the industry spent $4.8 billion on DTC advertising, a 13 percent increase over 2005 and the second year of double-digit growth.

Deals: Roche Goes Shopping

May 1, 2007

Back in 2003, Roche resolved a long-standing lawsuit with Igen International by acquiring the company. As part of the deal, Roche acquired a perpetual license to use the Igen technology that gave rise to the lawsuit—electrochemiluminescence (ECL)—in certain applications. Igen's ECL patents, meanwhile, were assigned to a new publicly held spin-off company focusing on biosecurity testing, clinical point-of-care products, and vaccines. In March, Roche announced that it was acquiring the spin-off, Maryland-based BioVeris, for $21.50 per share, or a total of about $600 million.

Finance: Q&A with Annette Grimaldi

March 1, 2007

The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.

Pharm Exec Q&A: Japanese Wedding

May 1, 2006

Just how traditional marriages join a couple together from a common culture, Daiichi and Sankyo are merging based on a sense of having come from the same place, and facing the same future. But the art of integration lies in creating new ways of working that make the marriage bigger than the sum of its parts. Officiating the marriage is John Alexander, MD, head of pharma development for Daiichi Sankyo.

Deal Making: Who's Coming to the Table

April 1, 2006

Acquired: Intellectual property and technologies related to RNAi, therapeutics for respiratory diseases From: Galenea, Cambridge, MA By: Nastech Pharmaceutical Company, Bothell, WA Terms: Not disclosed

Finance: Promotional Productivity

March 1, 2006

Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.

Seven Principles for Fostering Partnerships

October 1, 2005

The backbone of the business development process is a series of decision gates with agreed upon decision criteria, and clear expectations for the appropriate levels of research and analysis for each stage in the process.

It's All Academic: Biotechs Looking to Universities

October 1, 2005

Academic institutions look for a strong committment from the company's senior management, favorable deal terms, market depth in a specific therapeutic area, and alignment with the partner's core strategy.

Successful Alliances: Novartis and Idenix Share the Secrets of Success

October 1, 2005

When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way.

ADVERTISEMENT

Click here